Self-assembled nanostructures of L-ascorbic acid alkyl esters support monomeric amphotericin B.
Amphiphilic drugs
Coagels
Drug carriers
Langmuir monolayers
Polyene macrolides
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
04
05
2020
revised:
03
11
2020
accepted:
19
01
2021
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
9
2
2021
Statut:
epublish
Résumé
Amphotericin B (AmB) is a highly effective antimicrobial, with broad antimycotic and antiparasitic effect. However, AmB poor water-solubilisation and aggregation tendency limits its use for topical applications. We studied the capacity of nanostructures formed by alkyl esters of L-ascorbic acid (ASCn) to solubilise AmB and tested the relationship between the prevalence of the monomeric form of AmB and its effectiveness as antimicrobial agent. We developed self-assembled nanostructures formed by the commercial compound, palmitoyl ascorbic acid, as well as the shorter chained myristoyl and lauroyl ascorbic acid. AmB loaded ASCn nanostructures were studied by a combination of spectroscopic techniques, together with particle analysis, differential scanning calorimetry, microbiological tests, and Langmuir monolayer visualisation. We found no direct relation between the antimicrobial capacity and the prevalence of the monomeric form of the drug. However, the later was related to chemical stability and colloidal robustness. Nanostructures formed by ASC16 in its anionic state provide an appropriate environment for AmB in its monomeric form, maintaining its antimicrobial capacity. Langmuir film visualisation supports spectrophotometric evidence, indicating that ASC16 allows the in-plane solubilisation of AmB. Coagels formed by ASC16 appear as promising for carrying AmB for dermal delivery.
Identifiants
pubmed: 33553743
doi: 10.1016/j.heliyon.2021.e06056
pii: S2405-8440(21)00161-4
pmc: PMC7848660
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e06056Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Sci Rep. 2018 Sep 5;8(1):13253
pubmed: 30185887
Biophys Chem. 2008 Oct;137(2-3):110-5
pubmed: 18718697
Curr Drug Deliv. 2015;12(4):406-14
pubmed: 25772153
Antimicrob Agents Chemother. 1992 Nov;36(11):2518-22
pubmed: 1489196
Yeast. 1998 Jan 30;14(2):115-32
pubmed: 9483801
Mol Pharm. 2018 Sep 4;15(9):4202-4213
pubmed: 30081640
J Control Release. 2003 Feb 21;87(1-3):23-32
pubmed: 12618020
Drug Dev Ind Pharm. 2019 Apr;45(4):560-567
pubmed: 30632399
Ther Deliv. 2016 Sep;7(9):639-47
pubmed: 27582235
Antimicrob Agents Chemother. 1997 Nov;41(11):2345-51
pubmed: 9371331
J Pharm Sci. 2011 Jan;100(1):252-9
pubmed: 20602350
J Ocul Pharmacol Ther. 2012 Apr;28(2):102-9
pubmed: 22060001
Int J Pharm. 2010 Mar 15;387(1-2):236-43
pubmed: 20005934
Arch Dermatol. 1966 Jan;93(1):101-5
pubmed: 5900690
J Pharm Sci. 2008 Jul;97(7):2405-25
pubmed: 17893903
Biophys J. 2006 Jun 1;90(11):4104-18
pubmed: 16533859
Phys Chem Chem Phys. 2017 Nov 15;19(44):30078-30088
pubmed: 29098221
Molecules. 2018 Dec 18;23(12):
pubmed: 30567325
Drugs. 2009;69(3):361-92
pubmed: 19275278
Colloids Surf B Biointerfaces. 2020 Jan 1;185:110621
pubmed: 31726308
Lancet Infect Dis. 2007 Sep;7(9):581-96
pubmed: 17714672
J Ethnopharmacol. 1988 Jul-Aug;23(2-3):127-49
pubmed: 3057288
Mol Membr Biol. 2014 Mar-May;31(2-3):85-94
pubmed: 24650150
Biochim Biophys Acta. 2013 Nov;1828(11):2496-505
pubmed: 23806650
Eur J Pharm Sci. 2002 Jul;16(1-2):37-43
pubmed: 12113889
Pharmazie. 2005 Oct;60(10):751-5
pubmed: 16259122
Biochemistry. 1991 Jun 11;30(23):5707-15
pubmed: 2043613
J Phys Chem B. 2014 Dec 4;118(48):13821-32
pubmed: 25384264
Langmuir. 2016 Jan 19;32(2):587-95
pubmed: 26694518
Antimicrob Agents Chemother. 1992 Oct;36(10):2310-5
pubmed: 1444311
Int J Antimicrob Agents. 2000 Feb;13(4):243-8
pubmed: 10755238
Mol Pharm. 2012 May 7;9(5):1511-20
pubmed: 22506900
FEBS Lett. 1999 Sep 24;458(3):271-7
pubmed: 10570923
Biochim Biophys Acta Biomembr. 2017 Oct;1859(10):1891-1899
pubmed: 28642044
Int J Pharm. 2017 May 15;523(1):15-32
pubmed: 28323096
Sci Rep. 2017 Sep 19;7(1):11873
pubmed: 28928478
Drug Dev Ind Pharm. 2018 Oct;44(10):1693-1700
pubmed: 29936874
Int J Pharm. 2007 Dec 10;345(1-2):26-34
pubmed: 17964094
Biophys Chem. 2008 Jul;136(1):44-9
pubmed: 18472206
Biochim Biophys Acta. 2014 Mar;1838(3):731-8
pubmed: 24315999
Biochem Biophys Res Commun. 2011 Dec 9;416(1-2):7-12
pubmed: 22100811
J Wound Ostomy Continence Nurs. 2003 Jan;30(1):11-6
pubmed: 12529589
Biochim Biophys Acta. 1993 Oct 10;1152(1):185-8
pubmed: 8399298
Int J Pharm. 2006 Feb 17;309(1-2):234-40
pubmed: 16406402
Molecules. 2015 Dec 24;21(1):E6
pubmed: 26712721
Drug Dev Ind Pharm. 2006 Aug;32(7):821-7
pubmed: 16908419
Eur J Pharm Sci. 2013 Sep 27;50(1):114-22
pubmed: 23643736
Eur J Pharm Biopharm. 2010 Nov;76(3):443-9
pubmed: 20832470
Langmuir. 2011 Sep 6;27(17):10914-9
pubmed: 21766856
Int J Pharm. 2004 Feb 11;270(1-2):279-86
pubmed: 14726142
Biochim Biophys Acta. 2010 Nov;1798(11):2124-30
pubmed: 20699086
Biopolymers. 2002;67(1):49-55
pubmed: 11842413
J Colloid Interface Sci. 2015 Nov 1;457:232-42
pubmed: 26188730
Biophys Chem. 1997 May 21;66(1):1-12
pubmed: 17029866
Chirality. 2013 Jul;25(7):427-32
pubmed: 23695916
Biomaterials. 2014 Mar;35(8):2529-42
pubmed: 24382332
Drug Dev Ind Pharm. 2015 May;41(5):780-90
pubmed: 24654936